We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Maxcyte Inc | LSE:MXCT | London | Ordinary Share | COM STK USD0.01 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 295.00 | 290.00 | 300.00 | 295.00 | 295.00 | 295.00 | 5,668 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 41.29M | -37.92M | -0.3664 | -10.07 | 381.93M |
Date | Subject | Author | Discuss |
---|---|---|---|
15/1/2021 15:26 | Agreed - and holding RENE too. Meanwhile, looking forward to the RNS here next week. | someuwin | |
15/1/2021 12:45 | o/t I come in peace acknowledging there will be lots of smart people on MCXT thread who might appreciate RENE story which has stealth morphed into a mRNA / CRISPR story Check out this Twitter thread... | the stigologist | |
14/1/2021 22:30 | Truly sobering article Nimbo, thank you for the link. Telephone numbers... | assagai | |
14/1/2021 21:36 | Barrons article estimates therapy market for crispr sickle disease is $4.8 billion p.a. Thats larger than the c.$1.6 I have read in all the analyst sell side notes. Maxcyte have a single digit royalty agreed on the sickle cell drug. Its going to be an interesting few years here. | nimbo1 | |
14/1/2021 16:46 | Two companies where shareholders on these boards dreamt of Nasdaq listings were Quindell and Burford. Better to focus on the company's ability to sell its wares than its shares. | trident5 | |
14/1/2021 16:02 | I see Crispr on a march again today. Up 150% since early november. Oh dreams of a NASDAQ listing.... | assagai | |
14/1/2021 14:49 | Maxcyte is presenting at this 3 day virtual event "Edison Open House: Global Healthcare - DISCOVER THE LEADERS & INNOVATORS OF 2021" Registration via | pob69 | |
14/1/2021 08:07 | MaxCyte made a named appearance in Allogene's JPM presentation, as a technology partner. Page 22. Allogene is also committing publicly to initiation of a registrational trial for ALLO-501A in 2H21. A registrational study should attract low single digit $m milestone payments (guessing ~$3m) for MaxCyte across the duration of the study (I think there are multiple smaller triggers). The next step following this phase, if successful, would be to seek FDA approval. | gsbmba99 | |
13/1/2021 10:13 | Got them at 6.29 but only , I think because someone let a few out at mid. | assagai | |
13/1/2021 10:09 | Postings in green ink, large emboldened red font - time to bail? | trident5 | |
13/1/2021 09:54 | Level 2 is 4 v 1, so not surprised it's difficult to buy anything... That UT last night at 6.50 was ridiculous, a very clear message that somebody wanted the run of up days to end! | 74tom | |
13/1/2021 09:44 | Trying to add another 2750 , nothing doing yet. | assagai | |
13/1/2021 09:37 | Not much time to buy ahead of next news... "...Based on ongoing momentum in transformational cell therapies and milestone payments from growth in clinical and commercial license partnerships, MaxCyte expects financial results to be ahead of market expectations for the full-year in the core life sciences business (before CARMA costs). A more detailed trading update will be announced the week of 18 January 2021. MaxCyte continues to work with Locust Walk on the strategy and future funding of the Group's CARMA business, and enrolment and dosing in the existing CARMA no-preconditioning MCY-M11 clinical study is continuing well. The Company will provide a further update in January." | someuwin | |
12/1/2021 18:03 | Interesting closing share price One UT trade for 100 shares at 650p setting the close. No other trades close to that during the day. When the share price was 610 - 630p all the trades at 617 were actually Buys. Something going on in the background. | acuere | |
12/1/2021 09:22 | Currently you're getting two companies for the price of one. * MXCT which is the 'picks & shovels' gene & cell therapy tools business (with royalties from partner products) * CARMA Cell Therapies - mRNA based cell therapies for cancer and other diseases. With a Phase I clinical trial for ovarian cancer underway. We'll hear more about their plans for CARMA (spin out?, trade sale?, farm in?, IPO?) and clinical progress later this month. Realising value from CARMA should provide a big uplift here. | someuwin | |
11/1/2021 11:30 | It's so quiet, I can still hear that echo :-) | walter walcarpets | |
11/1/2021 11:24 | Echo that. | assagai | |
11/1/2021 11:12 | As an indication of the lack of awareness of Mxct look at the Lse BB. Only 6 posts since July when share price was 217p. And none at all since 24th Nov. Quiet BBs always a good sign for me. | acuere | |
11/1/2021 09:36 | This slide from last November shows the accelerating increase in the number of commercial partners. Second week into 2021 and they bag another one! MXCT will just keep getting bigger and bigger. | someuwin | |
11/1/2021 08:45 | Hi someuwin...it's been on some of our radars for sometime now, but agree that this is still undervalued in the market given its potential. It's hard to find all the undervalued shares in the market....good luck anyway ! | multibagger | |
11/1/2021 08:44 | Yes, I'm amazed at the lack of awareness of this stock. It must surely be on it's way to being a multi-billion stock. | someuwin | |
11/1/2021 08:34 | I'm averaging up on MXCT...circa £57,900 order gone in :) Edit: Filled 9259 shares@ 625p Good luck all ! | multibagger | |
11/1/2021 07:54 | Excellent news to start the week, and rather surprising how quiet this thread is. MXCT still under the radar? | saucepan |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions